resolvins and protectins: specialized pro-resolving .../media/files/activity files... · resolvins...

PREPUBLICATION COPY: UNCORRECTED PROOFS

Resolvins and Protectins: Specialized Pro-Resolving Mediators in

Inflammation and Organ Protection: Metabolomics of Catabasis

Charles N. Serhan1

INTRODUCTION A highly regulated inflammatory response and its timely resolution is the ideal outcome

of an acute inflammatory response essential for ongoing health. Hence the cellular and molecu-lar mechanisms that govern natural resolution are vital. Using an unbiased metabolomic-based systems approach to profile self-limited inflammatory exudates, namely, by studying acute in-flammatory responses that resolve on their own the author and colleagues identified novel potent chemical mediators. These new chemical mediators constitute a genus of specialized pro-resolving lipid mediators (SPM) comprised of three new families coined the resolvins, protectins and most recently the maresins biosynthesized from omega-3 fatty acids. These novel local chemical signals join the lipoxin and aspirin-triggered lipoxins as potent anti-inflammatory and pro-resolving lipid mediators formed from the n-6 EFA arachidonic acid (Serhan, 2007). SPM are each stereoselective in their actions and as a defining bioaction for this genus they each fami-ly member controls both the duration and magnitude of the inflammatory response as well as re-duces leukocyte mediated injury from within and pain signals. Mapping these endogenous reso-lution circuits had already provided new avenues to appreciate the molecular basis of many widely occurring diseases that are associated with uncontrolled inflammation. The focus of this IOM presentation/review is to overview our current understand and recent advances on the bio-synthesis and actions of these novel anti-inflammatory, pro-resolving and protective lipid media-tors biosynthesized from dietary essential fatty acids including EPA and DHA. Also, emphasis herein is on the neuroprotective actions of these local mediators that may be relevant in trauma and brain injury and means to enhance their local biosynthesis from the recent literature. Currently the most widely used anti-inflammatory therapies are directed at inhibiting specific enzymes and/or antagonism of specific receptors for pro-inflammatory mediators (Brennan and McInnes, 2008). Both selective cyclooxygenase inhibitors and anti-tumor necrosis factor α (TNF-α) are examples of this clinical approach. The goal of this approach is to block the production of pro-inflammatory chemical mediators that reduced both the signs and symptoms of inflammation and local tissue damage (Brennan and McInnes, 2008; Flower, 2003). Research efforts within the author’s laboratory focus on profiling self-limited inflammation and uncover-ing novel mechanisms that terminate the local acute inflammatory response and stimulate resolu-tion with the return of the tissue to homeostasis in murine systems in vivo—a process known as catabasis or the return from disease or the battle front. Identification of these biochemical and cellular processes demonstrated that for the first time that the process of resolution, once consi-dered a passive process, is actually an active programmed process at the level of the tissue (for recent reviews see Serhan, 2007; Serhan et al., 2008). The resolution as a passive event was

1 Center for Experimental Therapeutics and Reperfusion Injury, Harvard Institutes of Medicine, Brigham and Women’s Hospital and Har-vard Medical School, Boston, MA

2 NUTRITION, TRAUMA, AND THE BRAIN


thought to simply burn out with the dilution of chemotactic gradients that recruit leukocytes to an infection or invading organism. Natural resolution of self-limited challenges as well as limited second organ injury proved to be an active process in that we found evidence for temporal activation of biochemical pathways that biosynthesis mediators that instruct the tissue and inflammatory white cells to re-solve. Research in the author’s laboratory focused on the potential use of these endogenous agonists to stimulate natural resolution of inflammation rather than targeting inhibition or anta-gonism of inflammation. This approach has also opened a new understanding of the mechanisms underlying chronic inflammatory diseases as well as a new area in molecular pharmacology, namely resolution pharmacology. The essential omega-3 fatty acids, in particular eicosapentae-noic acid (EPA) and docosahexaenoic acid (DHA), are precursors to a several families of media-tors in this new genus of potent lipid mediators (LM) that are both pro-resolving and anti-inflammatory (specialized pro-resolving mediators: SPM).

AN IDEAL OUTCOME An acute inflammatory response initiated by microbial invasion or tissue damage is cha-racterized by the cardinal signs of inflammation, i.e. heat, redness, swelling and pain (Majno, 1975). These signs and symptoms are accompanied by a well known set of cellular microscopic events, including edema and the accumulation of leukocytes, specifically polymorphonuclear leukocytes (PMN), followed by monocytes that differentiate locally to macrophages (Cotran et al., 1999) (Figure 1). The local acute inflammatory response is protective for the host and serves to maintain tissue homeostasis. If uncontrolled, this vital response can become deleterious for the host and the process can progress to chronic inflammation, scarring and fibrosis rather than ter-minate or resolve. In many cases, the fundamental cause of tissue damage is excessive leukocyte accumulation (Cassatella, 2003). In traumatic brain injury, for example excessive neutrophil in-filtration amplifies local tissue damage (Cotran et al., 1999; Majno and Joris, 2004).

The Resolution Program In self-limited resolving inflammatory reactions, leukocyte recruitment is coupled with release of local factors that prevent further or excessive trafficking of leukocytes, allowing for resolution (Serhan et al., 2000; Serhan et al., 2002). We found that, early in the initiation phase of an inflammatory response, pro-inflammatory mediators such as prostaglandins and leuko-trienes play an important role (Samuelsson et al., 1987). Indeed, monkeys fed a diet lacking es-sential fatty acids were found to be defective at mounting an efficient inflammatory response (Palmblad et al., 1988). This highlights the importance of arachidonate-derived eicosanoids or the n-6 EFA contribution to controlled acute inflammation. In this report from Palmblad et al, both neutrophil (PMN) chemotaxis and superoxide generation in response to the chemotactic peptide fMLF were markedly abrogated when the cells isolated from monkeys feed n-3 EFA. This is important to our appreciation of the action of dietary n-3 in non-human primates because the PMN that normally defends the body can release reactive oxygen species ideally intended to kill invading organisms phagocytosized by white cells. Instead, when they are summand into surrounding tissues that are already damage these cells can inadvertently spill noxious reactive oxygen species that can further destroy tissue. The finding that dietary n-3 reduce this potentially deleterious response of white cells ex vivo provides evidence from primates that leukocyte me-diated tissue damage can be reduced with dietary EFA. The molecular mechanism for this reduc-

RESOLVINS AND PROTECTINS 3


tion in leukocyte mediated events was not known at the time of the Palmblad et al. report but ap-pears to be related to the now known actions of the SPM (see below).

Figure 1. Decision paths in acute inflammation. Several outcomes of acute inflammation caused by infection or injury are possible, including progression to chronic inflammation, tissue fibrosis and wound healing/scarring or, in the ideal scenario, complete resolution (Majno, 1975). The cardinal signs of inflammation – calor (heat), rubor (redness), tumor (swelling), dolor (pain) and loss of function -- have been known as the visual signs of inflammation apparent to ancient civilizations. Chronic inflammation was viewed as the persistence of an acute inflammatory re-sponse. The chronic inflammatory diseases widely observed in the West are rheumatoid arthritis and periodontal disease. There is now considerable interest in inflammation because it is consi-dered to be the pathophysiologic basis of many diseases that were traditionally not considered to be inflammatory in their pathobiology. These include diabetes, cardiovascular diseases and asthma, to name a few.



Progression from acute to chronic inflammation as in many widely occurring human dis-eases of concern in public health such as periodontal disease, arthritis (Koopman and Moreland, 2005) and cardiovascular disease (Libby, 2008), to name a few, is widely viewed as an excess of pro-inflammatory mediators (Van Dyke and Serhan, 2006). Complete termination of an acute inflammatory insult is also pertinent for restoration of tissue homeostasis and is necessary for ongoing health. Key to this process is the complete removal of leukocytes from inflammatory sites without leaving remnants of the host’s combat between leukocytes, invading microbes, and/or other initiators of inflammation that can seed or amplify the local inflammatory response. Evidence from the author’s laboratory and many others (e.g. Morris et al., 2009) now indicates that the resolving phase of inflammation is not merely a passive process as once believed, but actively takes place as a programmed response at the tissue level (reviewed in Serhan, 2007; Serhan et al., 2008), which can be viewed as analogous to the cellular level or programmed cell death (Cohen et al., 1992). Although mononuclear cells can sometimes contribute to pro-inflammatory responses (Cotran et al., 1999), they are also critical in wound healing, tissue re-pair and remodeling in a non-inflammatory, non-phlogistic (non-fever causing) manner (Serhan and Savill, 2005). This important homeostatic role of monocytes and macrophages is termed ef-ferocytosis (Tabas, 2010).

SPECIALIZED PRO-RESOLVING LIPID MEDIATORS AND NUTRITION: NOT JUST N-6 VS. N-3 IN THE CONTROL OF

INFLAMMATION— A TEMPORAL PROGRESSION TO CATABASIS The new genus of EFA-derived autacoids were coined specialized pro-resolving media-tors (SPM) because they possess families of potent anti-inflammatory, pro-resolving and protec-tive mediators in experimental animal models of disease (reviewed in Serhan, 2007). These in-clude the lipoxins from n-6 arachidonic acid (Levy et al., 2001) as well as the n-3-derived resolvins, protectins and the newly identified maresins, which are not reviewed herein (see Serhan et al., 2009). These novel families of endogenous lipid-derived mediators were originally isolated from self-limited inflammatory murine exudates captured during the natural resolution phase (Figures 2 and 3). Each of these local chemical mediators is actively biosynthesized via distinct cellular, and in some cases transcellular, enzymatic pathways that are stereocontrolled to produce molecules that are stereoselective in their actions. Hence SPM are potent agonists that control the duration and magnitude of inflammation by acting on specific receptors (e.g. GPCR) on separate cell populations to stimulate the overall resolution of inflammation (Serhan and Chiang, 2008).

A systems metabolomics approach was taken using mass spectrometry to analyze the en-dogenous mediators and mechanisms temporally biosynthesized in vivo by exudates to actively resolve inflammation (Figure 2). For this, the murine dorsal air pouch system proved to be very useful because self-limited inflammatory exudates could easily be obtained (Serhan et al., 2000; Serhan et al., 2002). This system permitted direct exudate analysis in terms of lipidomics and lipid mediator metabolomic profiling (e.g. bioactive autacoids, as well as their inactive precur-sors and further metabolites), proteomics, and cellular composition by monitoring leukocyte traf-ficking. Importantly, utilizing this approach made it possible to determine when and where dif-ferent families of local mediators were biosynthesized during resolution (Bannenberg et al., 2005; Serhan, 2007).



Figure 2. Systems approach to metabolomics of resolution. Illustration of the systems ap-proach taken for the differential analysis of inflammatory exudates. For these initial studies, the murine air pouch was used because it provided a convenient means to assess tissue level res-ponses by studying the histology as well as the temporal and spatial relationships between infil-trating leukocytes and inflammatory mediators that are initiated by proinflammatory stimuli such as bacteria, microbial products or cytokines such as TNFα. This differential temporal analysis of inflammatory exudates comparing cellular composition, lipid mediator lipidomics and proteo-mics has also been carried out in oral inflammation, peritonitis, airway and lung inflammation, renal ischemia-reperfusion injury and stroke (see text for further details).



Figure 3. Specialized pro-resolving mediators are generated during inflammatory resolu-tion: ideal outcome of inflammation. Using a rigorous definition of acute inflammation and its resolution (Cotran et al., 1999) illustrated lower left, we found that acute inflammation initiates a lipid mediator class switch from prostaglandins and leukotrienes in the initial phases to lipoxins and proresolving mediators to resolution and the return to homeostasis. Alternatively, an unre-solved acute inflammatory response can persist and become chronic inflammation, and in this case lipid mediators such as prostaglandins and leukotrienes are elevated and lead from chronic inflammation to tissue fibrosis. Resolution is an active process switched on by specialized pro-resolving mediators (SPM), including E-series resolvins derived from omega-3 PUFA eicosapen-taenoic acid (Serhan et al., 2000), D-series resolvins biosynthesized from docosahexaenoic acid (DHA) (Serhan et al., 2002; Sun et al., 2007), as well as the protectins (Serhan et al., 2006; Serhan et al., 2002). From these results we can now consider the tissue level events of acute in-flammation as programmed resolution (see text for further details).



Lipoxins were the first anti-inflammatory and pro-resolving lipid mediators recognized, signaling the resolution of acute contained inflammation (Serhan, 2005). Lipoxins are lipoxyge-nase-derived eicosanoids derived enzymatically from arachidonic acid, an omega-6 or n-6 EFA that is released from phospholipid stores during inflammation (Samuelsson et al., 1987). In hu-mans they are biosynthesized via transcellular metabolic processes engaged during leukocyte interactions with mucosal cells, i.e., epithelia of the gastrointestinal tract or bronchial tissue, and within the vasculature during platelet–leukocyte interactions (Serhan, 2007). The murine dorsal air pouch was used to determine the formation and roles of endogenous lipoxin A4 (LXA4) in the resolution of acute inflammation (Levy et al., 2001). Upon initiation of inflammation with TNF-α, there was a typical acute-phase response denoted by rapid PMN infiltration preceded by gen-eration of local prostaglandins and leukotrienes. Unexpectedly, the eicosanoids then underwent a temporal progression in local mediators we termed a “class switch”. As exudates evolve, the ei-cosanoid profiles switch and the lipid mediators produced within the milieu of the exudate changes (Levy et al., 2001). Within the inflammatory exudate, arachidonate-derived eicosanoids changed from initial production of prostaglandins and leukotrienes to lipoxins, which halted fur-ther recruitment of neutrophils. This class switch was driven in part by COX-derived prostaglan-dins E2 and D2 that regulate the transcription of enzymes involved in lipoxin biosynthesis (Levy et al., 2001). Hence, with Sir John Savill, I introduced the concept that “alpha signals omega,” the beginning signals the end in inflammation (Serhan and Savill, 2005). This became evident because the appearance of lipoxins within inflammatory exudates was concomitant with the loss of PMN and resolution of inflammation (Levy et al., 2001).

In the inflammatory milieu, neutrophils, undergo either apoptosis or necrotic cell death at the site of battle and must be removed. As part of the resolution circuit, lipoxins are biosynthe-sized (Levy et al., 2001) and signal macrophages to engulf/take up the apoptotic PMN (Godson et al., 2000). Lipoxins also proved to be potent chemoattractants for mononuclear cells, but in a non-phlogistic manner. LX activates monocyte infiltration without stimulating release of pro-inflammatory chemokines or activation of pro-inflammatory gene pathways in these cells. Thus, LX actively reduced the entry of PMN to the site of inflammation while accelerating uptake of apoptotic PMN (Serhan, 2007). Lipoxins are potent anti-inflammatory mediators that are formed and act in picogram to nanogram amounts within human tissues and in animal disease models (Serhan, 2005). They have the specific pro-resolution actions of limiting PMN recruitment, che-motaxis, and adhesion to the site of inflammation, acting essentially as a braking signal for PMN-mediated tissue injury (Morris et al., 2009; Serhan, 2005). Additionally, lipoxin stable ana-logs activate endogenous anti-microbial defense mechanisms (Canny et al., 2002) and thus un-like many other anti-inflammatory treatments LX are not immunosuppressive.

SPM ARE BIOSYNTHESIZED FROM THE OMEGA-3 ESSENTIAL FATTY ACIDS: EPA AND DHA

Dietary omega-3 polyunsaturated fatty acids (PUFA) are known to carry protective ef-fects in the cardiovascular system, many inflammatory disorders and neural function (Leon et al., 2008; Salem et al., 2001; Simopoulos, 2008). Importantly, Hibbeln and colleagues have shown that reduced serum levels of DHA can lead to severe physiological outcomes including depres-sion and increased suicide (Hibbeln, 1998). This reduction in circulating levels of n-3 correlated with low consumption in humans. Hence Captain Hibbeln introduced the concept of nutritional armor to help emphasize the important role of dietary DHA and to underscore the need to bal-ance this potential for DHA and other EFA deficits in the diet in particular those of the military



diet given the stress and potential for tissue trauma. The molecular mechanisms by which ome-ga-3 PUFAs exert their biological effects in general were incomplete and needed to be elucidated at the cellular and molecular levels. The prevailing theory on the actions of n-3 fatty acids (DHA, EPA) is that they compete for arachidonic acid in phospholipid stores, blocking the biosynthesis of eicosanoids that are proinflammatory such as leukotrienes and prostaglandins as well as va-soactive thromboxane. For an elegant review of this thesis, the readers are directed to Lands (2005). This competition between n-3 and n-6 pathways is evident with results from many stu-dies and is demonstrable in vitro with isolated cells and enzymes with high concentrations of EFA (e.g. micro- to millimolar range) particularly DHA and EPA. New results indicate that many of the n-6 eicosanoids play important protective roles in resolution and host defense. Thus, these new findings raise critical questions regarding reducing n-6 EFA levels as relevant in hu-man physiology. To this end, the author has addressed the question “Are the essential omega-3 PUFAs such as EPA and DHA enzymatically converted locally in vivo to novel bioactive media-tors? Do these local mediators serve as effectors or agonists in vivo?” Accordingly, using an un-biased metabolomic approach, mice given omega-3 PUFA biosynthesized novel lipid mediators during the resolution phase of acute inflammation. These mediators are potent agonists of many responses relevant in the immune system and organ protection, particularly neuroprotection. Given the pathophysiology that accompanies traumatic brain injury (TBI) it is highly likely that the SPM will have a beneficial role in TBI by limiting further tissue damage and protecting neu-rons from uncontrolled inflammatory cells summoned to the TBI damaged tissue site (vide infra) (Serhan et al., 2000; Serhan et al., 2002).

RESOLVINS: RESOLUTION-PHASE INTERACTION PRODUCTS FROM N-3 EFA

Resolvins are a family of new local mediators enzymatically produced within resolving inflammatory exudates. They were initially identified using a systems approach with LC-MS-MS-based lipidomics and informatics and subsequently complete structural elucidation of these bioactive mediators and related compounds was achieved (Arita et al., 2005a; Hong et al., 2003; Serhan et al., 2000; Serhan et al., 2006; Serhan et al., 2002). The term resolvins or resolution-phase interaction products refers to endogenous compounds biosynthesized from the major omega-3 fatty acids EPA and DHA, denoted E series (RvE) and D series (RvD) resolvins respec-tively (Serhan et al., 2002) (Figures 4 and 5). Similar to lipoxins, resolvins can also be produced by a COX-2-initiated pathway in the presence of aspirin to give ‘aspirin-triggered’ (AT) forms. Accruing evidence indicates that resolvins possess potent anti-inflammatory and immunoregula-tory actions that include blocking the production of pro-inflammatory mediators and regulating leukocyte trafficking to inflammatory sites (reviewed in Serhan et al., 2008) as well as clearance of neutrophils from mucosal surfaces (Campbell et al., 2007). Specifically, resolvins limit PMN transendothelial migration in vitro and infiltration in vivo (Serhan et al., 2002; Sun et al., 2007). The potency of these compounds is notable, with concentrations as low as 10 nM producing ap-proximately 50 percent reduction in PMN transmigration. A more detailed description of the specific mechanistic actions of resolvins is discussed in (Serhan, 2007 and references cited within). Recent results established the stereochemistry and the stereoselective bioactions of RvD1, AT-RvD1, RvE1 and PD1/NPD1 (vide infra) as well as their further enzymatic inactiva-tion because at the end of resolution these signal are “turned off” (Arita et al., 2005a; Serhan et al., 2006; Sun et al., 2007).



Figure 4. Resolvin E1: structure and actions. Addition of TNF to murine air pouch leads to rapid infiltration of PMN into the inflammatory exudate. As the PMN levels declined, increased production of resolvin E1 derived from EPA was first identified (Serhan et al., 2000). The com-plete stereochemistry and the mechanism of action for RvE1 has been established (Arita et al., 2005a; Arita et al., 2007). Resolvins are defined as resolution phase interaction products and proved to be, on a molar basis, log orders more potent than traditional nonsteroidal anti-inflammatory drugs including aspirin.



Figure 5. Biosynthetic scheme of Resolvins. The complete stereochemistry of RvD1 and RvD2 has been established (Spite et al., 2009a; Sun et al., 2007). It is important to note that the actions of these endogenous SPM are mediated through specific receptors. RvE1 acts as an agonist on at least two G-protein-coupled receptors (GPCRs), namely ChemR23 and as a partial agonist on the LTB4 receptor (BLT1), thus competing with LTB4 for binding (Arita et al., 2005a; Arita et al., 2006). Recent research has revealed that RvE1 stimulates phosphorylation of Akt in a time and dose-dependent manner via direct activation of ChemR23 (Ohira et al., 2009). This agonist of resolution therefore displays a distinct mechanism of action compared to LXA4 that inhibits downstream tyrosine phosphorylation in eosinophils (Starosta et al., 2008). Additionally, a recent study identified two separate GPCRs that RvD1 specifically binds on human leukocytes, namely the LXA4 receptor (ALX) and GPR32, an or-phan receptor, which were validated using a GPCR β-arrestin coupled system (Krishnamoorthy et al., 2010). Identification of receptors for other omega n-3-derived SPM are in progress and are likely to be high-affinity GPCRs based on the potency of these newly discovered agonists of res-olution. Thus at least two GPCRs for each SPM, RvE1, RvD1 and LXA4, that are shared by AT-LXA4. Hence the concept that one ligand can act on a repertoire of receptors is not surprising in view of recent results on neuronal responses with the formyl peptide receptors including FPR2, peptides and LXA4

, which unexpectedly evokes chemosensory actions (Riviere et al., 2009).



PROTECTINS AND NEUROPROTECTIN D1: ORGAN-PROTECTIVE MEDIATORS

In addition to D-series resolvins, DHA is also a precursor for the family of protectins. These mediators are biosynthesized via a separate pathway (Figure 6). Protectins are distin-guished by their conjugated triene-containing structure (Serhan et al., 2006). The name “protec-tins” was coined from the observed anti-inflammatory and protective actions in neural tissues and systems (Hong et al., 2003). The prefix neuroprotectin gives the tissue location of their gen-eration and local actions, such as neuroprotectin D1 (NPD1) (Mukherjee et al., 2004; Serhan et al., 2006). Like the resolvins, protectins stop PMN infiltration and enhance macrophage phago-cytosis of apoptotic (dead cells) PMN (Hong et al., 2003; Serhan et al., 2006). They are biosyn-thesized by and act on glial cells and reduce cytokine expression (Hong et al., 2003).

Figure 6. Protectins: structure and actions. The complete stereochemistry of neuroprotectin D1 (NPD1) or protectin D1 (PD1) when generated in inflammatory exudates has been estab-lished (Serhan et al., 2006). NPD1 stops further neutrophilic infiltration in a number of in vivo animal systems as well as reduces microglial cell cytokine expression. These initial actions de-fined the biological functions and roles of PD1. In addition, in collaboration with Nicolas Bazan and colleagues, we have found that NPD1 reduces stroke damage and retinal injury (see Bazan et al., 2010)



Of special interest for this report, NPD1 reduces both retinal and corneal injury and stroke damage (Marcheselli et al., 2003), and improves corneal wound healing in mouse models (Gronert et al., 2005) (see Serhan, 2007; Serhan et al., 2008 and references cited within). DHA is well known for its role in neuronal systems and, along with AA, is a major PUFA found in the retina (Bazan et al., 2010). The available results provide the biological basis for the actions of NPD1 derived from DHA. In recent reviews we considered in detail the results obtained from several independent lines of investigation required to address the structure of the potent bioactive NPD1/PD1 (see Bazan et al., 2010). As with other bioactive mediators, such as the eicosanoids (Samuelsson et al., 1987), it is important to establish the stereochemistry of the compound and/or mediator. Notably, because subtle structurally changes in these and related products can be less active, inactive or even in some cases display opposing biologic actions as a result of subtle changes in stereochemistry that are recognized in biologic systems. To confirm the proposed basic structure and establish the complete stereochemistry, these studies on the 10,17S-docosatriene termed NPD1/PD1 included results from a) biosynthesis studies; b) matching of materials prepared by total organic synthesis with defined stereochemistry; and c) the actions of these and related compounds in biological systems (Ariel et al., 2005; Hong et al., 2003; Marcheselli et al., 2010; Mukherjee et al., 2004; Serhan et al., 2006; Serhan et al., 2002). We al-so consider these findings as they appeared in the literature with the goal of providing a clear and rigorous account of the evidence that supports the structure and bioactions of NPD1/PD1. Inves-tigations along these lines were required to establish the complete structure and potent actions of NPD1/PD1 and related endogenous products biosynthesized from DHA because the small amounts of NPD1 attainable from biological systems precluded direct stereochemical analyses of the products identified in retinal pigmented epithelial (RPE) cells. For a recent review, see (Bazan et al., 2010).

Briefly, the novel 10,17S-docosatriene was coined NPD1/PD1 given its potent actions in vivo noted above, which were identified first in (Hong et al., 2003; Serhan et al., 2002). Its basic structure was established and displayed potent anti-inflammatory actions, i.e., reducing PMN numbers in vivo and reducing the production of inflammatory cytokines by glial cells. Moreover, during the resolution phase of peritonitis, unesterified DHA levels increase in resolving exudates, where it appears to promote catabasis or the return to homeostasis following tissue insult, via conversion to D-series resolvins and 10,17S- docosatrienes (Bannenberg et al., 2005) by shorten-ing the resolution interval of an inflammatory response in vivo (Schwab et al., 2007).

In collaboration with Dr. Bazan and colleagues at LSU, we found next that the DHA-derived 10,17S-docosatriene was generated in vivo in the brain during experimental stroke in the ipsilateral cerebral hemisphere following focal ischemia (Figures 6, 7 and 8). We also demon-strated its potent bioactions in stroke, where NPD1/PD1 limited the entry of leukocytes, downre-gulated both COX-2 expression and NFκB activation and decreased infarct volume (Figure 8 from Marcheselli et al., 2003). Of interest, 10,17S-docosatriene is also formed in the human re-tinal pigment epithelial cell line ARPE-19 and introduced the term neuroprotectin D1 based on its neuroprotective bioactivity in the stroke model and RPE cells (Mukherjee et al., 2004). Also NPD1 proved to be a potent signal to inactivate pro-apoptotic and pro-inflammatory signaling. The capital D in NPD1 refers to its being the first identified neuroprotective mediator derived from DHA (Mukherjee et al., 2004).



Figure 7. Neuroprotectin D1 (NPD1/PD1) Biosynthesis and Actions. NPD1 was identified initially in murine exudates and next in murine brain cells. Fish such as trout also produce PD1/NPD1, indicating that this is a primordial structure and pathway. In the immune system, T cells skew to a Th2 cell in the presence of interleukin-4, increase their 15-LO type 1 and convert DHA to protectin D1. The actions of PD1 are denoted in the inset boxes. The biosynthesis of PD1 and its complete stereochemistry have been established. The conversion of DHA to protec-tin D1 enzymatically proceeds via the enzymatic epoxidation and formation of a key 16(17)-epoxy-DHA intermediate that is enzymatically converted to the complete stereochemistry re-quired for full biological action in PD1 (see text for further details).



Figure 8. Neuroprotective action of NPD1/PD1. Neuroprotectin D1 reduces stroke volume and leukocyte-mediated tissue damage in a murine model of focal ischemia in stroke. Figure is from Marcheselli et al., J. Biol. Chem. 2003; 278:43807-43817. See Bazan et al. (2010) and text for further details.

In parallel to these investigations, biosynthesis and function studies were carried out with human TH2-skewed peripheral blood mononuclear cells (PBMC) (Ariel et al., 2005). When pro-duced by human PBMC, PD1 promotes T cell apoptosis via the formation of lipid raft-encoded signaling complexes and reduced T-cell traffic in vivo. Matching materials prepared by total or-ganic synthesis determined the complete stereochemistry of the PBMC DHA-derived product. NPDl/PDl generated by human PBMC carried the complete stereochemistry of (10R,17S)-dihydroxydocosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid and was matched to the most potent bioactive product (Figure 7) using several dihydroxytriene-containing DHA-derived products isolated from human PBMC, human PMN and murine exudates (Ariel et al., 2005; Serhan et al., 2006).

With the stereochemistry of NPD1/PD1 established, its identification in human material was sought and found in exhaled breath condensates from human asthmatics (Levy et al., 2007) as well as in human brain tissue. NPD1 is present in both control brain tissues and at reduced levels in brain tissues from patients with Alzheimer’s disease (Lukiw et al., 2005 and Table 1). In addition, PD1 is a major product in bone marrow of female rats fed EPA and DHA (Poulsen et al., 2008). PD1 is also generated in vivo during ischemia-reperfusion of renal tissues, where it has profound actions, reducing the deleterious consequences of ischemia-reperfusion in renal tis-



sues (Duffield et al., 2006) in agreement with our earlier findings in brain tissues (Marcheselli et al., 2003).

With the complete stereochemistry and synthetic compound in hand, it was possible to demonstrate for the first time that PD1 activates resolution programs in vivo and shortens the resolution time of experimental inflammation in animal models (Schwab et al., 2007). Also, with the total organic synthesis route of NPD1/PD1, it was possible to radiolabel and isolate 3H-NPD1/PD1 made from the synthetic intermediate. With this radiolabel, we define for the specific binding sites present with ARPE-19 cells (Kd ~ 31 pM/mg cell protein) for 3H-NPD1/PD1 as well as specific binding to human neutrophils (Kd of ~25 nM) (Marcheselli et al., 2010).

Recent results using an LC-MS-MS profiling approach demonstrated that PD1 is made during the resolution of Lyme disease infections in mice (Blaho et al., 2009). NPD1 inhibits re-tinal ganglion cell death (Qin et al., 2008), is renal protective (Hassan and Gronert, 2009), and regulates adiponectin (González-Périz et al., 2009). Of interest, the double dioxygenation prod-uct 10S,17S-diHDHA, isomer of NPD1/PD1, was recently shown to have actions on platelets, reducing platelet aggregation at 0.3 µM, 1 µM and higher concentrations (Chen et al., 2009). In peritonitis, this isomer also showed biological activity but was less potent than NPD1/PD1 (Chen et al., 2009; Serhan et al., 2006). It is noteworthy that NPD1/PD1 and the resolvins are produced by trout tissues including trout brain from endogenous DHA, suggesting that these structures are highly conserved from fish to humans (Hong et al., 2005) and that we still have much to learn regarding the bioactions and functions of NPD1/PD1, the D-series and E-series resolvins and re-lated products in human physiology and pathophysiology as well as in biological systems such as fish or in bone marrow, where the actions of NPD1/PD1 remain to be fully appreciated.

OMEGA-3 EFA AND SUBSTRATE AVAILABILITY IN RESOLUTION OF INFLAMMATION

To elucidate the role of EPA, DHA, and AA during inflammation in vivo, we studied dis-ease models in wild-type mice with mice that overexpress the C. elegans fat-1 gene to compare the effects of omega-3 and -6 PUFAs. This gene converts omega-6 PUFA into omega-3 resulting in elevated tissue levels of omega-3 PUFA within the fat-1 overexpressing mice. In a model of oxygen-induced retinopathy, a protective effect against pathological angiogenesis was found in the retina when there was a lower ratio of omega-6:omega-3 PUFA. Wild-type mice lacking the fat-1 transgene had more extensive vaso-obliteration and more severe retinal neovascularization compared with fat-1 mice (Connor et al., 2007). In mice fed omega-3 PUFA, biosynthetic mark-ers of NPD1 and RvE1 were detected in the retinal tissues. In mice without omega-3 PUFA sup-plementation, administration of RvD1, RvE1, or NPD1 gave protection from vaso-obliteration and neovascularization (Connor et al., 2007), as well as suture-induced ocular inflammation (Jin et al., 2009). These fat-1 mice also have increased levels of resolvins and protectins in the colon and are protected from colitis (Hudert et al., 2006). In evolving exudates, rapid appearance of unesterified omega-3 PUFA parallels the initial increase in edema (Kasuga et al., 2008). Thus, omega-3 precursors for resolving and protectin biosynthesis in exudates become available direct-ly from the peripheral circulation. This contrasts with the pool or storage of AA and other EFA that requires phospholipase A2 for liberation for example in inflammatory cells (Dennis, 2000; Lands, 2005) and in retina RPE cells (Bazan et al., 2010).



SPM IN INFLAMMATORY EXPERIMENTAL DISEASE SYSTEMS Inflammatory bowel disorders, such as colitis, are characterized by a relapsing inflamma-

tory process as a result of local mucosal damage and abnormal mucosal responses. In a well ap-preciated experimental colitis in mice, mice are challenged with an intrarectal antigenic hapten, 2,4,6-trinitrobenzene sulfonic acid (TNBS) to induce colitis, RvE1 was protective against bowel inflammation (Arita et al., 2005b). With treatment of as little as 1 microgram of RvE1 per mouse, there was dramatic reduction in mortality, weight loss, and less severe histologic display of colitis, namely reduction in the associated inflammatory cells, such as PMN and lymphocytes, compared with mice with TNBS-induced colitis. RvE1 is also protective in Porphyromonas gin-givalis-induced periodontal disease in rabbits, where it appears to stimulate tissue regeneration of the periodontium (Hasturk et al., 2007). Another pro-resolving action of RvE1 was evident in a murine model of fatty liver disease, where RvE1 administration to obese mice significantly alle-viated hepatic steatosis and restored the loss of insulin sensitivity (Gonzalez-Periz et al., 2009).

The complete stereochemical assignment for RvD2 (Figure 2) was recently established as 7S,16R,17S-trihydroxy-4Z,8E,10Z,12E,14E,19Z-docosahexaenoic acid (Spite et al., 2009a). RvD2 proved very potent suggesting it may have a broad role in vivo and potential application in disease. Sepsis remains a clinical challenge with increasing prevalence and mortality rates. In these cases, infection progresses rapidly unless contained and cleared by phagocytes, and epi-thelial and endothelial barrier dysfunction results in immune suppression, multiple-organ failure and death. Administration of omega-3 PUFA in some of these cases of sepsis has shown favora-ble outcomes (Singer et al., 2008), although the mechanism of action is still being studied. In an established mouse model of sepsis, initiated by ‘mid-grade’ cecal ligation and puncture (CLP) surgery, RvD2-methyl ester (RvD2-ME; 100ng) was protective (Spite et al., 2009a). After 12h, mice that underwent CLP surgery had severe bacterial burden both locally within the peritoneum and systemically, which was accompanied by a significant leukocyte infiltrate to the peritoneal cavity. RvD2-ME treatment immediately following CLP significantly reduced both blood and peritoneal bacterial levels and dramatically limited local PMN influx. Septic mice were hypo-thermic 12h after CLP and displayed a drastic decrease in activity levels, whereas RvD2-treated mice remained active within their cages and their body temperatures were similar to sham-operated control mice. The proportion of mice that survived 7 days following ‘mid-grade’ CLP was approximately 36%. RvD2-ME was able to double the survival rates (Figure 5). Interesting-ly, whereas all of the mice that did not survive in the vehicle-treated group died by 36h, 25% of the mice that died in the RvD2-treated group lived until 48h post-CLP, suggesting that RvD2 may increase the ‘therapeutic window’ that could afford additional time for further interventions such as antibiotics. Further analysis of peritoneal exudates showed a ‘cytokine-storm’ of both pro-inflammatory cytokines and other mediators associated with detrimental outcomes in sepsis, as well as elevated pro-inflammatory lipid mediators LTB4 and PGE2. RvD2-ME significantly blunted overzealous cytokine production and pro-inflammatory lipid mediators measured 12h post-CLP. Dissection of mouse inguinal lymph nodes revealed that bacteria were disseminated throughout this organ in vehicle-CLP mice, whereas RvD2 enhanced phagocyte-dependent bac-terial containment and clearance. Corroboratory results were obtained in vitro with human PMN exposed to RvD2 (1 and 10 nM) that showed increased phagocytosis and killing of E. coli (Spite et al., 2009a). These novel findings highlight that RvD2 is protective in mucosal barrier breakage and leakage leading to sepsis.

A recent study found that RvE1 is also anti-infective, enhancing clearance of bacteria from mouse lungs in a model of pneumonia, leading to increased survival (Seki et al., 2010).



Thus, pro-resolving mediators display anti-inflammatory, anti-fibrotic and recently demonstrated anti-infective actions in several widely used laboratory models of inflammation (see Table 1). Together, these results indicate SPM, i.e. resolvins, are not immunosuppressive but rather en-hance the innate anti-microbial systems in phagocytes and mucosal epithelial cells (Canny et al., 2002). Table 1. SPM Actions in Animal Disease Models Relevant to TBI and DHA* Disease model Species Action(s) References Resolvin E1 Periodontitis Rabbit Reduces neutrophil infiltration; prevents

connective tissue and bone loss; promotes healing of diseased tissues; regenerates lost soft tissue and bone

(Hasturk et al., 2007; Hasturk et al., 2006)

Peritonitis Mouse Stops neutrophil recruitment; regulates che-mokine/cytokine production Promotes lymphatic removal of phagocytes

(Arita et al., 2005a; Bannenberg et al., 2005; Schwab et al., 2007)

Dorsal air pouch

Mouse Stops neutrophil recruitment

(Serhan et al., 2000)

Retinopathy Mouse Protects against neovascularization (Connor et al., 2007; Jin et al., 2009)

Colitis Mouse Decreases neutrophil recruitment and pro-inflammatory gene expression; improves survival; reduces weight loss

(Arita et al., 2005b)

Pneumonia Mouse Improves survival; decreases neutrophil in-filtration; enhances bacterial clearance; re-duces pro-inflammatory cytokines and che-mokines

(Seki et al., 2010)

Resolvin D1 Peritonitis Mouse

Stops neutrophil recruitment (Hong et al., 2003;

Spite et al., 2009b; Sun et al., 2007)

Dorsal skin air pouch

Mouse

Stops neutrophil recruitment (Hong et al., 2003; Serhan et al., 2002)

Kidney ische-mia-reperfusion

Mouse

Protects from ischemia-reperfusion-induced kidney damage and loss of function; regu-lates macrophages and protects from fibrosis

(Duffield et al., 2006)

Retinopathy Mouse

Protects against neovascularization (Connor et al., 2007; Jin et al., 2009)

Resolvin D2 Peritonitis Mouse

Stops neutrophil recruitment (Spite et al., 2009a)

Sepsis Mouse Improves survival; reduces pro-inflammatory cytokines; regulates neutrophil recruitment; enhances bacterial containment

(Spite et al., 2009a)



Protectin D1 Peritonitis Mouse

Stops neutrophil recruitment; regulates che-mokine/cytokine production; promotes lym-phatic removal of phagocytes; regulates T-cell migration

(Ariel et al., 2005; Arita et al., 2005a; Bannenberg et al., 2005; Schwab et al., 2007 )

Asthma Mouse

Protects from lung damage, airway inflam-mation and airway hyperresponsiveness

(Levy et al., 2007)

Human

Protectin D1 is produced in humans and is diminished in asthmatics

(Levy et al., 2007)

Kidney ische-mia-reperfusion

Mouse

Protects from ischemia-reperfusion-induced kidney damage and loss of function; regu-lates macrophages and is anti-fibrotic

(Duffield et al., 2006)

Retinopathy Mouse

Protects against neovascularization (Connor et al., 2007)

Ischemic stroke Rat

Stop leukocyte infiltration, inhibits NF-κB and cyclooxygenase-2 induction

(Marcheselli et al., 2003)

Alzheimer’s disease

Human

Diminished protectin D1 production in hu-man Alzheimer’s disease

(Lukiw et al., 2005)

Embryonic stem cells

Mouse and human

NPD1 promotes cardiac and neuronal stem cell differentiation

(Yanes et al., 2010)

Neural stem cells

Mouse LXA4 regulates neuronal stem cell gene ex-pression and proliferation

(Wada et al., 2006)

Acute stroke (focal cerebral ischemia reper-fusion)

Rat LXA4 reduces local infarct volume and apoptosis of neuronal cells; decreases lipid peroxidation and cytokine production

(Y e et al., 2010)

Traumatic brain injury (TBI)

Rat DHA reduces damage from impact accelera-tion injury; reduces beta amyloid precursor protein, a marker of axonal injury

(Bailes and Mills, 2010)

*The actions of each of the main resolvins and protectins listed were confirmed with compounds prepared by total organic synthesis (see text and cited references for details).

STEM CELLS AND RECENT RESULTS OF INTEREST FOR TRAUMATIC BRAIN INJURY

The identification and biosynthesis of resolvins and protectins from DHA in brain (Serhan et al., 2002) and microglial cells (Hong et al., 2003), and in view of their anti-inflammatory and pro-resolving actions in acute inflammation using in vivo models, suggested that these compounds may also be active in neural tissues. Indeed, neuroprotectin D1 limited neutrophilic infiltration in ischemic brain as well as reduced pro-inflammatory gene expression, suggesting that this compound had potent neuroprotective actions in local ischemia-reperfusion in the brain (Marcheselli et al., 2003), which was also observed in renal protection (Duffield et al., 2006; Hassan and Gronert, 2009) (Figure 6). Given the importance of neural stem cells in



organ regeneration, we examined the actions of leukotriene B4 and lipoxin A4 and found that mu-rine neural stem cells produced leukotriene B4 and possess leukotriene receptors. Lipoxin A4 re-gulated proliferation and differentiation of these cells. Of interest, the 15-epimer isomer of LXA4,( which is more stable in vivo as it is not inactivated as rapidly as LXA4) reduced neural stem cell growth at concentrations as low as 1 nanomolar. Gene chip analysis demonstrated that leukotriene B4 and LXA4 gave opposing gene expression profiles with neural stem cells. LTB4 induced proliferation and differentiation of neural stem cells into neurons and the regulatory ac-tions of LXA4 suggested that these new pathways may be relevant in restoring stem cells (Wada et al., 2006). Using a metabolomic approach with stem cells and evaluation of redox status, Yanes et al. recently found that neuroprotectin D1 is produced, which in turn showed potent ac-tions at the 10-nanomolar range in promoting neural differentiation as well as cardiac stem cell differentiation (Yanes et al., 2010). Hence, the local molecular response to injury and local in-flammation may generate these local mediators, lipoxin A4 and neuroprotectin D1, to regulate organ stem cells to initiate tissue repair and regulate the local inflammatory response.

The neuroprotection effects of lipoxin A4 have also been confirmed and extended by oth-ers. For example, lipoxin A4 is neuroprotective in experimental stroke (Sobrado et al., 2009), and lipoxin A4 methyl ester reduced neutrophilic infiltration and protects rat brain from focal cerebral ischemia-reperfusion (Ye et al., 2010). In addition to the actions on leukocytes, lipoxin A4 also regulates cytokine production from human astrocytoma cells (Decker et al., 2009). Taken togeth-er, these findings in murine systems suggest that the arachidonic acid-derived SPM, namely li-poxins, are neuroprotective by downregulating local inflammatory response and limiting further inflammation via tissue destruction by limiting neutrophil-mediated tissue damage. Hence, ara-chidonic acid as substrate and an essential fatty acid plays a role in neuroprotection and particu-larly one that is regulated by dietary intake of essential fatty acids. Along these lines, Huang et al. reported that intravenous and dietary DHA significantly improves spinal cord injury in rats. Improvements and neuroprotection were obtained when DHA was injected i.v. with sustained dietary supplementation (Huang et al., 2007).

GAPS IN CURRENT KNOWLEDGE: TOO MUCH OF A GOOD THING? Recently, using a rat model of traumatic brain injury, Bailes and Mills (2010) found that

dietary supplementation with DHA reduced acceleration of injury. These are encouraging find-ings suggesting that DHA delivery can have a neuroprotective effect, likely via the local biosyn-thesis of pro-resolving and anti-inflammatory mediators such as neuroprotectin D1 and D-series resolvins produced from the exogenous DHA. However, there is a potential negative side for excess delivery of DHA above “optimal dietary levels,” the limits of which remain unknown at present. When excess DHA is available to undergo nonenzymatic autooxidation, neurotoxic products can be produced, such as trans-4-hydroxy-2-hexenal (Long et al., 2008). Likewise, in isolated neuroblastoma cells, we recently found that resolvins and protectins are not produced from DHA by these tumor cells in vitro but rather exogenous DHA is converted to hydroperoxy acid intermediates that are cytotoxic (Gleissman et al., 2010). For a cancer cell type, this may be a beneficial approach to killing tumor cells with exogenous DHA. The point taken from these experiments is that excess DHA can lead to oxidation products that can further amplify local in-flammation and tissue damage at the cellular level. Along these lines, the enzymatically pro-duced resolvin D1 reduces inflammation initiated by lipid oxidation products (Spite et al., 2009b). Taken together, these results suggest that optimal dietary levels of DHA could be processed in vivo to enhance production of neuroprotective local mediators. Thus, a clear start-



ing point in humans is to establish the daily dose required for DHA and the levels that ought to be considered in excess for healthy individuals. In this regard, potential gender and age differ-ences need to be taken into consideration for future studies. In considering traumatic brain inju-ries on the battlefield, the currently available animal results suggest that i.v. delivery of DHA in addition to dietary supplementation can have neuroprotective actions. These neuroprotective ac-tions may be mediated by enhanced local production of resolvins and protectins. Indeed, if local conversion of dietary DHA to resolvins and protectins can be established in humans with TBI and stress, then dietary DHA could speed recovery time for military personnel. Because DHA is a natural product and has been shown in many studies to be safe in humans (Lands, 2005), DHA supplementation can be recommended for military personnel. This can also open the opportunity to gain direct evidence for DHA effectiveness in clinical studies with military personnel (see be-low).

SUMMARY AND RECOMMENDATIONS In summation, acute inflammation initiated by neutrophils in response to injury or micro-

bial invasion is, ideally, a self-limited response that is protective for the host. Excessive uncon-trolled inflammatory responses can lead to chronic disorders as well as further tissue injury, as in the case of TBI. Neutrophil-derived pro-inflammatory mediators, including leukotrienes and prostaglandins, can amplify this process. Within contained inflammatory exudates, we found that neutrophils change phenotype to initiate resolution and begin to biosynthesize pro-resolving and protective local mediators from essential fatty acids including AA, DHA and EPA. There is an active catabasis to return tissues to a homeostatic healthy state from the battle of host defense to microbes during inflammatory episodes (Bannenberg et al., 2005). SPM such as lipoxins, protec-tins, and resolvins biosynthesized locally from essential fatty acids (EFA) accelerate this process and the return to tissue homeostasis (Schwab et al., 2007). Each of these SPM is temporally and spatially biosynthesized to actively regulate resolution by acting on specific receptors (Serhan et al., 2008), initiating anti-inflammatory and pro-resolving signals to terminate the inflammatory response and limit further tissue injury. Hence, dietary EFA in experimental animal models re-viewed herein directly regulate the magnitude and duration of local acute inflammation via the production of potent local chemical mediators that are pro-resolving. These experimental find-ings in animal models that demonstrate pathophysiologic events relevant to TBI (Table 1), taken together, suggest that increasing the n-3 EFA in military personnel to boost their n-3 status may have a salutary impact on traumatic tissue injury to limit the magnitude of the response. Helping to optimize the host’s response to injury and local inflammation with nutritional substrates may also represent a cost-effective means to reduce recovery times in the field. Of note, our recent findings indicate that resolvins are also potent modulators reducing pain in murine systems (Bang et al., 2010; Sommer and Birklein, 2010; Xu et al., 2010).

The answer to the question “Is there enough evidence from TBI animal models to con-clude that military personnel should boost their n-3 status to protect against the effects of TBI?” is yes, but additional information from both human and animal studies is needed to directly sup-port the cause-and-effect relationships between increasing DHA status and reducing TBI and other indications in military personnel. Because the identification of DHA metabolome in resolu-tion of acute inflammation with the production of potent local protective and anti-inflammatory mediators in murine systems is relatively recent (see Serhan, 2007), additional results are needed to establish cause-and-effect relationships in TBI and, for example, increased resolvins and neu-roprotectins or SPM and reduced tissue inflammation and local damage. The results reviewed



herein suggest that the protective actions of DHA in rat TBI (Bailes and Mills, 2010) are me-diated locally by resolvins and protectins, given their potent actions in in vivo models of inflam-mation in animals (Table 1).

With these metabolomic tools and structures now available in synthetic form from our present laboratory-based research efforts (Serhan, 2010), these possibilities and suggestions can be directly tested and evaluated rigorously in the field to assess their validity for military imple-mentation. For example, human studies are needed to establish:

• Is DHA a “green pro-drug”? Is it converted locally with trauma to D-series resolvins

and protectins, which in turn are bioactive mediators that limit tissue inflammation and further tissue damage?

• What is the relationship between serum/plasma DHA levels and reduced TBI and/or ear injury in military personnel? Is there a gender selectivity for DHA conversion, ac-tions, and overall impact?

• Do resolvins and/or protectins from DHA mediate cellular protection and reduce TBI damage and recovery time?

• Can excess serum DHA levels lead to enhanced autooxidation pathways in stressed military personnel or protection and enhanced SPM biosynthesis?

• What are the pathway biomarkers for resolvins and protectins that can be monitored in peripheral blood of military personnel? For example, do 17-HDHA, 14-HDHA, 22-hydroxy-DHA, RvD5, 7,17-diHDHA, NPD1, RvD1 or RvD2 correlate with DHA le-vels and/or the degree of protection in TBI and/or ear trauma? Do they reduce recov-ery times for military personnel?

In addition to these human studies, mechanism of action studies can be carried out with

animal experiments. These can also include direct comparisons between administration of NPD1, RvD1, RvD2 vs. DHA in animal models of TBI and ear injury. Assessment of the role of sub-strate (e.g. DHA) levels in transgenic mice with elevated tissue DHA such as the fat-1 mouse (Hudert et al., 2006), which show protection from inflammatory disorders as well as elevated levels of resolvins and protectins. Murine models with transgenic overexpressing proresolving receptors (Devchand et al., 2003; Krishnamoorthy et al., 2010) can be used to determine the role of resolvin receptors in protection from TBI. These animal and human studies can be imple-mented in parallel to increase the DHA status in military personnel in order to gain mechanistic insight and fill gaps in current knowledge of the role of EFA and n-3 status in reducing trauma and shortening the time required for recovery of military personnel.

ACKNOWLEDGEMENTS The authors thank Mary H. Small for expert assistance with manuscript preparation and

the members of the laboratory and collaborators for their expertise and efforts in the reports refe-renced herein. Research in the author’s laboratory reviewed here was supported by National In-stitutes of Health grants DK-074448 and GM-38765 (C.N.S).

Conflict of interest statement: The author is inventor on patents assigned to Brigham and Women’s Hospital and Part-

ners HealthCare on the composition of matter, uses, and clinical development of anti-



inflammatory and pro-resolving lipid mediators. These are licensed for clinical development. The author retains founder stock in Resolvyx Pharmaceuticals.



ABBREVIATIONS AA, arachidonic acid EPA, eicosapentaenoic acid DHA, docosahexaenoic acid LX, lipoxin LXA4, 5S, 6R,15S-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid PUFA, polyunsaturated fatty acid PMN, polymorphonuclear leukocytes Protectins, biosynthesized from DHA, containing conjugated triene structures and are protective

mediators PD1/NPD1, protectin D1/neuroprotectin D1, 10R,17S-dihydroxy-docosa-

4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid Resolvins, structurally unique and potent bioactive local mediators; E series from EPA and D

series from DHA RvD1, resolvin D1, 7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid AT-RvD1, aspirin-triggered-resolvin D1, 7S,8R,17R-trihydroxy-docosa-

4Z,9E,11E,13Z,15E,19Z-hexaenoic acid RvD2, resolvin D2, 7S,16R,17S-trihydroxy-4Z,8E,10Z,12E,14E,19Z-docosahexaenoic acid RvE1, resolvin E1, 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid



REFERENCES Ariel, A., P .-L. Li, W. Wang, W.-X. Tang, G. Fredman, S. Hong, K. H. Gotlinger, and C. N. Serhan.

2005. The docosatriene protectin d1 is produced by th2 skewing and promotes human t cell apoptosis via lipid raft clustering. J. Biol. Chem. 280:43079-43086.

Arita, M., F. Bianchini, J. Aliberti, A. Sher, N. Chiang, S. Hong, R. Yang, N. A. Petasis, and C. N. Serhan. 2005a. Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolvin e1. J. Exp. Med. 201:713-722.

Arita, M., S. Oh, T. Chonan, S. Hong, S. Elangovan, Y .-P . Sun, J. Uddin, N. A. Petasis, and C. N. Serhan. 2006. Metabolic inactivation of resolvin e1 and stabilization of its anti-inflammatory actions. J. Biol. Chem. 281:22847-22854.

Arita, M., T. Ohira, Y . P. Sun, S. Elangovan, N. Chiang, and C. N. Serhan. 2007. Resolvin e1 selectively interacts with leukotriene b4 receptor blt1 and chemr23 to regulate inflammation. J. Immunol. 178:3912-3917.

Arita, M., M. Yoshida, S. Hong, E. Tjonahen, J. N. Glickman, N. A. Petasis, R. S. Blumberg, and C. N. Serhan. 2005b. Resolvin e1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. U.S.A. 102:7671-7676.

Bailes, J. E., and J. D. Mills. 2010. Docosahexaenoic acid (DHA) reduces traumatic axonal injury in a rodent head injury model. J. Neurotrauma:doi: 10.1089/neu.2009.1239.

Bang, S., S. Yoo, T. J. Yang, H. Cho, Y . G. Kim, and S. W. Hwang. 2010. Resolvin d1 attenuates activation of sensory transient receptor potential channels leading to multiple anti-nociception. Br. J. Pharmacol. 161:707-720.

Bannenberg, G. L., N. Chiang, A. Ariel, M. Arita, E. Tjonahen, K. H. Gotlinger, S. Hong, and C. N. Serhan. 2005. Molecular circuits of resolution: Formation and actions of resolvins and protectins. J. Immunol. 174:4345-4355.

Bazan, N. G., J. M. Calandria, and C. N. Serhan. 2010. Rescue and repair during photoreceptor cell renewal mediated by docosahexaenoic acid-derived neuroprotectin d1. J. Lipid Res. 51:2018-2031.

Blaho, V . A., M. W. Buczynski, C. R. Brown, and E. A. Dennis. 2009. Lipidomic analysis of dynamic eicosanoid responses during the induction and resolution of lyme arthritis. J. Biol. Chem. 284:21599-21612.

Brennan, F. M., and I. B. McInnes. 2008. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118(11):3537-3545.

Campbell, E. L., N. A. Louis, S. E. Tomassetti, G. O. Canny, M. Arita, C. N. Serhan, and S. P . Colgan. 2007. Resolvin e1 promotes mucosal surface clearance of neutrophils: A new paradigm for inflammatory resolution. F ASEB J. 21:3162-3170.

Canny, G., O. Levy, G. T. Furuta, S. Narravula-Alipati, R. B. Sisson, C. N. Serhan, and S. P . Colgan. 2002. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (bpi) in human mucosal epithelia. Proc. Natl. Acad. Sci. USA 99:3902-3907.

Cassatella, M. A., ed. 2003. The neutrophil. V ol. 83, Chem. Immunol. Allergy. Basel: Karger. Chen, P ., B. Fenet, S. Michaud, N. Tomczyk, E. Véricel, M. Lagarde, and M. Guichardant. 2009. Full

characterization of pdx, a neuroprotectin/protectin d1 isomer, which inhibits blood platelet aggregation. FEBS Lett. 583:3478-3484.

Cohen, J. J., R. C. Duke, V . A. Fadok, and K. S. Sellins. 1992. Apoptosis and programmed cell death in immunity. Annu Rev Immunol 10:267-293.

Connor, K. M., J. P. SanGiovanni, C. Lofqvist, C. M. Aderman, J. Chen, A. Higuchi, S. Hong, E. A. Pravda, S. Majchrzak, D. Carper, A. Hellstrom, J. X. Kang, E. Y . Chew, N. N. Salem, Jr., C. N. Serhan, and L. E. H. Smith. 2007. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med. 13:868-873.



Cotran, R. S., V . Kumar, and T. Collins, eds. 1999. Robbins pathologic basis of disease. 6th ed. Philadelphia: W.B. Saunders Co.

Decker, Y ., G. McBean, and C. Godson. 2009. Lipoxin a4 inhibits il-1beta-induced il-8 and icam-1 expression in 1321n1 human astrocytoma cells. Am. J. Physiol. Cell. Physiol. 296:1420-1427.

Dennis, E. A. 2000. Phospholipase a2 in eicosanoid generation. Am. J. Respir . Crit. Care Med. 161:S32-S35.

Devchand, P . R., M. Arita, S. Hong, G. Bannenberg, R.-L. Moussignac, K. Gronert, and C. N. Serhan. 2003. Human alx receptor regulates neutrophil recruitment in transgenic mice: Roles in inflammation and host-defense. F ASEB J. 17:652-659.

Duffield, J. S., S. Hong, V . Vaidya, Y . Lu, G. Fredman, C. N. Serhan, and J. V . Bonventre. 2006. Resolvin d series and protectin d1 mitigate acute kidney injury. J. Immunol. 177:5902-5911.

Flower, R. J. 2003. The development of cox2 inhibitors. Nat Rev Drug Discov 2(3):179-191. Gleissman, H., R. Yang, K. Martinod, M. Lindskog, C. N. Serhan, J. I. Johnsen, and P . Kogner. 2010.

Docosahexaenoic acid metabolome in neural tumors: Identification of cytotoxic intermediates. F ASEB J. 24:906-915.

Godson, C., S. Mitchell, K. Harvey, N. A. Petasis, N. Hogg, and H. R. Brady. 2000. Cutting edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 164:1663-1667.

Gonzalez-Periz, A., R. Horrillo, N. Ferre, K. Gronert, B. Dong, E. Moran-Salvador, E. Titos, M. Martinez-Clemente, M. Lopez-Parra, V . Arroyo, and J. Claria. 2009. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: A role for resolvins and protectins. F ASEB J 23(6):1946-1957.

González-Périz, A., R. Horrillo, N. Ferré, K. Gronert, B. Dong, E. Morán-Salvador, E. Titos, M. Martínez-Clemente, M. López-Parra, V . Arroyo, and J. Clària. 2009. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: A role for resolvins and protectins. F ASEB J. 23:1946-1957.

Gronert, K., N. Maheshwari, N. Khan, I. R. Hassan, M. Dunn, and M. L. Schwartzman. 2005. A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J. Biol. Chem. 280:15267-15278.

Hassan, I. R., and K. Gronert. 2009. Acute changes in dietary omega-3 and omega-6 polyunsaturated fatty acids have a pronounced impact on survival following ischemic renal injury and formation of renoprotective docosahexaenoic acid-derived protectin d1. J. Immunol. 182:3223-3232.

Hasturk, H., A. Kantarci, E. Goguet-Surmenian, A. Blackwood, C. Andry, C. N. Serhan, and T. E. Van Dyke. 2007. Resolvin e1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J. Immunol. 179:7021-7029.

Hasturk, H., A. Kantarci, T. Ohira, M. Arita, N. Ebrahimi, N. Chiang, N. A. Petasis, B. D. Levy, C. N. Serhan, and T. E. Van Dyke. 2006. Rve1 protects from local inflammation and osteoclast mediated bone destruction in periodontitis. F ASEB J. 20:401-403.

Hibbeln, J. R. 1998. Fish consumption and major depression. Lancet 351:1213. Hong, S., K. Gronert, P. Devchand, R.-L. Moussignac, and C. N. Serhan. 2003. Novel docosatrienes and

17s-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: Autacoids in anti-inflammation. J. Biol. Chem. 278:14677-14687.

Hong, S., E. Tjonahen, E. L. Morgan, L. Yu, C. N. Serhan, and A. F. Rowley. 2005. Rainbow trout (oncorhynchus mykiss) brain cells biosynthesize novel docosahexaenoic acid-derived resolvins and protectins -- mediator lipidomic analysis. Prostaglandins Other Lipid Mediat. 78:107-116.

Huang, W. L., V . R. King, O. E. Curran, S. C. Dyall, R. E. Ward, N. Lal, J. V . Priestley, and A. T. Michael-Titus. 2007. A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury. Brain Res. 130:3004-3019.

Hudert, C. A., K. H. Weylandt, J. Wang, Y . Lu, S. Hong, A. Dignass, C. N. Serhan, and J. X. Kang. 2006. Transgenic mice rich in endogenous n-3 fatty acids are protected from colitis. Proc. Natl. Acad. Sci. U.S.A. 103:11276-11281.



Jin, Y ., M. Arita, Q. Zhang, D. R. Saban, S. K. Chauhan, N. Chiang, C. N. Serhan, and R. Dana. 2009. Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest Ophthalmol Vis Sci 50(10):4743-4752.

Kasuga, K., R. Yang, T. F. Porter, N. Agrawal, N. A. Petasis, D. Irimia, M. Toner, and C. N. Serhan. 2008. Rapid appearance of resolvin precursors in inflammatory exudates: Novel mechanisms in resolution. J Immunol 181(12):8677-8687.

Koopman, W. J., and L. W. Moreland. 2005. Arthritis and allied conditions : A textbook of rheumatology. 15th ed. ed. Philadelphia, Pa. ; London: Lippincott Williams & Wilkins.

Krishnamoorthy, S., A. Recchiuti, N. Chiang, S. Yacoubian, C.-H. Lee, R. Yang, N. A. Petasis, and C. N. Serhan. 2010. Resolvin d1 binds human phagocytes with evidence for pro-resolving receptors. Proc. Natl. Acad. Sci. U.S.A. 107:1660-1665.

Lands, W. E. M. 2005. Fish, omega-3 and human health. 2nd ed. Champaign, IL: AOCS Press. Leon, H., M. C. Shibata, S. Sivakumaran, M. Dorgan, T. Chatterley, and R. T. Tsuyuki. 2008. Effect of

fish oil on arrhythmias and mortality: Systematic review. BMJ 337:a2931. Levy, B. D., C. B. Clish, B. Schmidt, K. Gronert, and C. N. Serhan. 2001. Lipid mediator class switching

during acute inflammation: Signals in resolution. Nat. Immunol. 2:612-619. Levy, B. D., P. Kohli, K. Gotlinger, O. Haworth, S. Hong, S. Kazani, E. Israel, K. J. Haley, and C. N.

Serhan. 2007. Protectin d1 is generated in asthma and dampens airway inflammation and hyper-responsiveness. J. Immunol. 178:496-502.

Libby, P . 2008. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 121(10 Suppl 1):S21-31.

Long, E. K., T. C. Murphy, L. J. Leiphon, J. Watt, J. D. Morrow, G. L. Milne, J. R. H. Howard, and M. J. Picklo, Sr. 2008. Trans-4-hydroxy-2-hexenal is a neurotoxic product of docosahexaenoic (22:6; n-3) acid oxidation. J. Neurochem. 105:714-724.

Lukiw, W. J., J. G. Cui, V . L. Marcheselli, M. Bodker, A. Botkjaer, K. Gotlinger, C. N. Serhan, and N. G. Bazan. 2005. A role for docosahexaenoic acid-derived neuroprotectin d1 in neural cell survival and alzheimer disease. J. Clin. Invest. 115:2774-2783.

Majno, G. 1975. The healing hand : Man and wound in the ancient world: Harvard University Press. Majno, G., and I. Joris. 2004. Cells, tissues, and disease: Principles of general pathology. 2nd ed. New

Y ork: Oxford University Press. Marcheselli, V . L., S. Hong, W. J. Lukiw, X. Hua Tian, K. Gronert, A. Musto, M. Hardy, J. M. Gimenez,

N. Chiang, C. N. Serhan, and N. G. Bazan. 2003. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 278:43807-43817.

Marcheselli, V . L., P. K. Mukherjee, M. Arita, S. Hong, R. Antony, K. Sheets, N. Petasis, C. N. Serhan, and N. G. Bazan. 2010. Neuroprotectin d1/protectin d1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukot. Essent. Fatty Acids 82:27-34.

Morris, T., M. Stables, A. Hobbs, P . de Souza, P. Colville-Nash, T. Warner, J. Newson, G. Bellingan, and D. W. Gilroy. 2009. Effects of low-dose aspirin on acute inflammatory responses in humans. J. Immunol. 183:2089-2096.

Mukherjee, P . K., V . L. Marcheselli, C. N. Serhan, and N. G. Bazan. 2004. Neuroprotectin d1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 101:8491-8496.

Ohira, T., M. Arita, K. Omori, A. Recchiuti, T. E. Van Dyke, and C. N. Serhan. 2009. Resolvin e1 receptor activation signals phosphorylation and phagocytosis. J. Biol. Chem. 285:3451-3461.

Palmblad, J., R. W. Wannemacher, N. Salem, Jr., D. B. Kuhns, and D. G. Wright. 1988. Essential fatty acid deficiency and neutrophil function: Studies of lipid-free total parenteral nutrition in monkeys. J Lab Clin Med 111(6):634-644.



Poulsen, R. C., K. H. Gotlinger, C. N. Serhan, and M. C. Kruger. 2008. Identification of inflammatory and pro-resolving lipid mediators in bone marrow and their profile alteration with ovariectomy and omega-3 intake. Am. J. Hematol. 83:437-445.

Qin, Q., K. A. Patil, K. Gronert, and S. C. Sharma. 2008. Neuroprotectin d1 inhibits retinal ganglion cell death following axotomy. Prostaglandins Leukot. Essent. Fatty Acids 79:201-207.

Riviere, S., L. Challet, D. Fluegge, M. Spehr, and I. Rodriguez. 2009. Formyl peptide receptor-like proteins are a novel family of vomeronasal chemosensors. Nature 459(7246):574-577.

Salem, N., Jr., B. Litman, H. Y . Kim, and K. Gawrisch. 2001. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36(9):945-959.

Samuelsson, B., S. E. Dahlen, J. A. Lindgren, C. A. Rouzer, and C. N. Serhan. 1987. Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science 237(4819):1171-1176.

Schwab, J. M., N. Chiang, M. Arita, and C. N. Serhan. 2007. Resolvin e1 and protectin d1 activate inflammation-resolution programmes. Nature 447:869-874.

Seki, H., K. Fukunaga, M. Arita, H. Arai, H. Nakanishi, R. Taguchi, T. Miyasho, R. Takamiya, K. Asano, A. Ishizaka, J. Takeda, and B. D. Levy. 2010. The anti-inflammatory and proresolving mediator resolvin e1 protects mice from bacterial pneumonia and acute lung injury. J Immunol 184(2):836-843.

Serhan, C. N. 2007. Resolution phases of inflammation: Novel endogenous anti-inflammatory and pro-resolving lipid mediators and pathways. Annu. Rev. Immunol. 25:101-137.

———. 2010. Novel resolution mechanisms in acute inflammation: To resolve or not? Am. J. Pathol.:Epub Sept. 2; doi: 10.2353/ajpath.2010.100322.

Serhan, C. N., and N. Chiang. 2008. Endogenous pro-resolving and anti-inflammatory lipid mediators: A new pharmacologic genus. Br J Pharmacol 153 Suppl 1:S200-215.

Serhan, C. N., N. Chiang, and T. E. Van Dyke. 2008. Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8:249-261.

Serhan, C. N., C. B. Clish, J. Brannon, S. P . Colgan, N. Chiang, and K. Gronert. 2000. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192:1197-1204.

Serhan, C. N., K. Gotlinger, S. Hong, Y . Lu, J. Siegelman, T. Baer, R. Yang, S. P . Colgan, and N. A. Petasis. 2006. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers: Assignments of dihydroxy-containing docosatrienes. J. Immunol. 176:1848-1859.

Serhan, C. N., guest ed. 2005. Special issue on lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukot. Essent. Fatty Acids 73(3-4):139-321.

Serhan, C. N., S. Hong, K. Gronert, S. P . Colgan, P . R. Devchand, G. Mirick, and R.-L. Moussignac. 2002. Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J. Exp. Med. 196:1025-1037.

Serhan, C. N., and J. Savill. 2005. Resolution of inflammation: The beginning programs the end. Nat. Immunol. 6:1191-1197.

Serhan, C. N., R. Yang, K. Martinod, K. Kasuga, P . S. Pillai, T. F. Porter, S. F. Oh, and M. Spite. 2009. Maresins: Novel macrophage mediators with potent anti-inflammatory and pro-resolving actions. J. Exp. Med. 206:15-23.

Simopoulos, A. P . 2008. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood) 233(6):674-688.

Singer, P ., H. Shapiro, M. Theilla, R. Anbar, J. Singer, and J. Cohen. 2008. Anti-inflammatory properties of omega-3 fatty acids in critical illness: Novel mechanisms and an integrative perspective. Intensive Care Med 34(9):1580-1592.

Sobrado, M., M. P . Pereira, I. Ballesteros, O. Hurtado, D. Fernández-López, J. M. Pradillo, J. R. Caso, J. Vivancos, F. Nombela, J. Serena, I. Lizasoain, and M. A. Moro. 2009. Synthesis of lipoxin a4 by 5-lipoxygenase mediates ppargamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J. Neurosci. 29(12):3875-3884.



Sommer, C., and F. Birklein. 2010. Fighting off pain with resolvins. Nat. Med. 16:518-520. Spite, M., L. V . Norling, L. Summers, R. Yang, D. Cooper, N. A. Petasis, R. J. Flower, M. Perretti, and

C. N. Serhan. 2009a. Resolvin d2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461:1287-1291.

Spite, M., L. Summers, T. F. Porter, S. Srivastava, A. Bhatnagar, and C. N. Serhan. 2009b. Resolvin d1 controls inflammation initiated by glutathione-lipid conjugates formed during oxidative stress. Brit. J. Pharmacol. 158:1062-1073.

Starosta, V ., K. Pazdrak, I. Boldogh, T. Svider, and A. Kurosky. 2008. Lipoxin a4 counterregulates gm-csf signaling in eosinophilic granulocytes. J Immunol 181(12):8688-8699.

Sun, Y .-P ., S. F. Oh, J. Uddin, R. Yang, K. Gotlinger, E. Campbell, S. P . Colgan, N. A. Petasis, and C. N. Serhan. 2007. Resolvin d1 and its aspirin-triggered 17r epimer: Stereochemical assignments, anti-inflammatory properties and enzymatic inactivation. J. Biol. Chem. 282:9323-9334.

Tabas, I. 2010. Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10:36-46.

Van Dyke, T. E., and C. N. Serhan. 2006. A novel approach to resolving inflammation. Sci. Am. Oral and Whole Body Health:42-45.

Wada, K., M. Arita, A. Nakajima, K. Katayama, C. Kudo, Y . Kamisaki, and C. N. Serhan. 2006. Leukotriene b4 and lipoxin a4 are regulatory signals for neural stem cell proliferation and differentiation. F ASEB J. 20:1785-1792.

Xu, Z.-Z., L. Zhang, T. Liu, J.-Y . Park, T. Berta, R. Yang, C. N. Serhan, and R.-R. Ji. 2010. Resolvins rve1 and rvd1 attenuate inflammatory pain via central and peripheral actions. Nat. Med. 16:592-597.

Yanes, O., J. Clark, D. M. Wong, G. G. Patti, A. Sánchez-Ruiz, H. P . Benton, S. A. Trauger, C. Desponts, S. Ding, and G. Siuzdak. 2010. Metabolic oxidation regulates embryonic stem cell differentiation. Nat. Chem. Biol. 6(6):411-417.

Y e, X.-H., Y . Wu, P.-P. Guo, J. Wang, S.-Y . Yuan, Y . Shang, and S.-L. Yao. 2010. Lipoxin a4 analogue protects brain and reduces inflammation in a rat model of focal cerebral ischemia reperfusion. Brain Res. 1323:174-183.

resolvins and protectins: specialized pro-resolving .../media/files/activity files... · resolvins...

Documents